Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature
Authors' conclusion
Triptorelin is effective not only in the treatment of CPP but also for children with short stature who exhibit premature sexual development, short PHA or impaired TH.
Study context
- Population
- Children with central precocious puberty (CPP) and short stature treated with triptorelin, June 2018 to May 202224 completed 1 year
- Participants
- 26 children
- Exposure
- Triptorelin monotherapy vs triptorelin plus growth hormone (GH)
- Triptorelin monotherapyn = 4
- Triptorelin + GHn = 22
- Outcome
- Predicted adult height (PHA)
- Follow-up
- 1 year
Main finding
As reported in the abstract
- Significant improvements in PHA in the 24 children who completed a 1-year treatment course
Observational data: associations, not effects.
Further findings
Treatment purpose
- Treated to improve height
- 24
- Treated for suppression of premature sexual development
- 2
Indication among 24 treated to improve height
- PHA-defined short stature
- 13
- Severely impaired target height (TH)
- 8
- Low TH
- 3
Bone age (BA) at start of triptorelin · start of treatment
- BA 9 to 11.5 years
- 21
- BA 11.5 to 13 years
- 3
- BA over 14 years
- 1
- 9-year-old boy with congenital adrenal hyperplasia (CAH), BA 16 years
- 1
Original publication
Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature. Clin Endocrinol (Oxf). Published 17 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →